Submit a manuscript Sign up for article alerts Contact us

RSS

Latest comments

Correction of trial design in the abstract (Mandira Paul, 21 October 2014)

In the first sentence under methods/design in the abstract the design is referred to as a non-superiority trial. This is incorrect and should be a non-inferiority trial, as is correctly stated in the remaining document. I am sorry for the inconvenience / first and corresponding author Mandira Paul read full comment

Comment on: Paul et al. BMC Women's Health, 14:98

Is this about cannilabisim??? (Rhona O'Connll, 03 April 2013)

Suggest rewording the title of this article which is not about 'eating competent low-income women' read full comment

Comment on: Lohse et al. BMC Women's Health, 13:12

Query about materials (Shaun Fountain, 05 November 2009)

Great series very useful for patient information.
It would be reassuring to know that the two deaths reported were not related to the tape procedure. read full comment

Comment on: Kaelin-Gambirasio et al. BMC Women's Health, 9:28

Author Contact Change (Noel Kim, 12 August 2009)

Please note that the contact information for the first author has changed. New contact info:

Noel N. Kim, PhD
6330 Nancy Ridge Drive, Suite 102
San Diego, CA 92121

nnkim@alaginresearch.com
noelkim@gmail.com read full comment

Comment on: Kim et al. BMC Women's Health, 6:14

Patient characteristics (William Stones, 19 August 2004)

This paper prompted me to follow up the question of whether the patients in the studies reviewed were allowed to take the combined oral contraceptive pill. This is not mentioned as a specific exclusion criterion in the published papers. Dr Sahin (reference 13) was kind enough to confirm that pill users were indeed excluded. A response is not forthcoming so far from the corresponding author for reference 9.Thus it seems to be a completely open question as to whether rofecoxib is effective for women using the combined oral contraceptive pill. This is rather extraordinary given that so many do use the pill in order to reduce dysmenorrhoea.Two other points came up during my search of the Vioxx licensing documentation on the FDA website. Firstly, it is reassuring to note that rofecoxib had no... read full comment

Comment on: Edwards et al. BMC Women's Health, 4:5